Bajaj Healthcare informs about press release

19 Mar 2025 Evaluate
Bajaj Healthcare has informed that Bajaj Healthcare has received recommendation from Subject Expert Committee (SEC) (Neurology & Psychiatry) of Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Cenobamate Tablets 12.5mg, 25mg, 50mg, 100mg, 150mg & 200mg. The press release in this regard, being issued by the Company.

The above information is a part of company’s filings submitted to BSE.

Bajaj Healthcare Share Price

359.75 17.20 (5.02%)
29-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.45
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2131.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×